Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Q2 2025
Kiniksa Pharmaceuticals International (KNSA) Q2 2025 earnings results (second quarter 2025)
10-Q filed Jul 29, 2025
Kiniksa Pharmaceuticals International (KNSA) reported revenue of $157M for the second quarter 2025 (Q2 2025), +44% from a year earlier and +14% from the quarter before. Operating margin was 12.9%, net earnings $17.8M (11.4% of revenue).
Kiniksa Pharmaceuticals International, Q2 2025: revenue $157M (+44% year over year), operating margin 12.9%, net earnings $17.8M, operating cash flow $28.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $157M | +14% | +44% |
| Operating profit | $20.2M | +52% | — |
| Net earnings | $17.8M | +109% | — |
| Operating cash flow | $28.1M | +26% | +444% |
| Free cash flow | $27.9M | +26% | +440% |
What changed
Revenue was $156.8M in Q2 2025, up 44% year over year and up 14% from the previous quarter.
Operating profit was $20.2M, a 12.9% margin (up 13.0 points year over year). Total costs grew 26% against revenue growth of 44%. The fastest-growing cost line was Other operating costs (+75%). Net earnings were $17.8M. The effective tax rate was 22.1%.
Operating cash flow was $28.1M (up 444% year over year), 158% of net earnings. Non-cash charges added back $358K of depreciation and amortization and $8.9M of share-based compensation. Capital expenditures of $165K left free cash flow of $27.9M.
Questions
What was Kiniksa Pharmaceuticals International's revenue in the second quarter 2025?
Kiniksa Pharmaceuticals International (KNSA) reported revenue of $157M for the second quarter 2025 (Q2 2025), +44% from a year earlier and +14% from the quarter before.
Was Kiniksa Pharmaceuticals International profitable in the second quarter 2025?
Operating profit was $20.2M (12.9% of revenue) and net earnings $17.8M.
Source: Kiniksa Pharmaceuticals International 10-Q on SEC EDGAR.